Libero Santarpia

Summary

Country: Italy

Publications

  1. pmc Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
    Serena Giunti
    Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, 50019 Firenze, Italy
    Int J Endocrinol 2013:803171. 2013
  2. pmc Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
    Libero Santarpia
    Department of Oncology, Translational Research Unit, Hospital of Prato and Istituto Toscano Tumori, 59100, Prato, Italy
    Breast Cancer Res Treat 134:333-43. 2012
  3. ncbi request reprint Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers
    Libero Santarpia
    Department of Oncology, Translational Research Unit, and Istituto Toscano Tumori, Prato Italy
    Curr Pharm Des 19:864-82. 2013
  4. doi request reprint Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
  5. doi request reprint Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Future Oncol 7:173-86. 2011
  6. doi request reprint Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
  7. pmc DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes
    Libero Santarpia
    Translational Research Unit, Department of Oncology, Istituto Toscano Tumori, Prato, Italy
    Oncologist 18:1063-73. 2013
  8. doi request reprint The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009
  9. doi request reprint Uncovering the metabolomic fingerprint of breast cancer
    Catherine Oakman
    Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Int J Biochem Cell Biol 43:1010-20. 2011
  10. doi request reprint A miRNA signature associated with human metastatic medullary thyroid carcinoma
    Libero Santarpia
    Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Relat Cancer 20:809-23. 2013

Detail Information

Publications12

  1. pmc Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma
    Serena Giunti
    Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, 50019 Firenze, Italy
    Int J Endocrinol 2013:803171. 2013
    ....
  2. pmc Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
    Libero Santarpia
    Department of Oncology, Translational Research Unit, Hospital of Prato and Istituto Toscano Tumori, 59100, Prato, Italy
    Breast Cancer Res Treat 134:333-43. 2012
    ..Simultaneous testing of many different mutations in a single needle biopsy is feasible and allows the design of prospective clinical trials that could test the functional importance of these mutations in the future...
  3. ncbi request reprint Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers
    Libero Santarpia
    Department of Oncology, Translational Research Unit, and Istituto Toscano Tumori, Prato Italy
    Curr Pharm Des 19:864-82. 2013
    ..Combination or sequential targeted therapies that are based on solid preclinical data regarding the inhibition of RET-mediated parallel or different -signalling pathways will likely be more effective...
  4. doi request reprint Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
    ..This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use...
  5. doi request reprint Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Future Oncol 7:173-86. 2011
    ..A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors...
  6. doi request reprint Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
    ..Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy...
  7. pmc DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes
    Libero Santarpia
    Translational Research Unit, Department of Oncology, Istituto Toscano Tumori, Prato, Italy
    Oncologist 18:1063-73. 2013
    ..In genes expressed in a bimodal fashion, RECQL4 was significantly associated with clinical outcome. In vitro studies showed that defects in RECQL4 impair homologous recombination, sensitizing BC cells to DNA-damaging agents. ..
  8. doi request reprint The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009
    ....
  9. doi request reprint Uncovering the metabolomic fingerprint of breast cancer
    Catherine Oakman
    Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Int J Biochem Cell Biol 43:1010-20. 2011
    ..The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer...
  10. doi request reprint A miRNA signature associated with human metastatic medullary thyroid carcinoma
    Libero Santarpia
    Departments of Endocrine Neoplasia and Hormonal Disorders Experimental Therapeutics Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Oncology, The University of Naples, Naples, Italy Department of Pathology, Centro Oncologico Fiorentino, Sesto Fiorentino, Florence, Italy Verna and Marrs McLean Department of Biochemistry and Molecular Biology Baylor College of Medicine, Houston, Texas, USA Department of Oncology, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy Department of Gynecologic Oncology, Center for RNA Interference and Non coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Endocrinology, University of Messina, Messina, Italy Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA Department of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Endocr Relat Cancer 20:809-23. 2013
    ..Our data identify a robust miRNA signature associated with metastatic MTC and distinct biological processes, e.g., TGFβ signalling pathway, providing new potential insights into the mechanisms of MTC metastasis...
  11. doi request reprint Targeting triple negative breast cancer: is p53 the answer?
    Natalie Turner
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy
    Cancer Treat Rev 39:541-50. 2013
    ..Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype...
  12. doi request reprint Breast cancer assessment tools and optimizing adjuvant therapy
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Nat Rev Clin Oncol 7:725-32. 2010
    ..The presence of drug targets and targetable signaling pathways, rather than molecularly defined subgroups, may ultimately drive treatment decisions...